R&D channel feed – Endpoints News

R&D channel feed

Arvinas, Pfizer’s PROTAC data fall short of hype in breast cancer

2 months ago

Beam shares promising first clinical data on gene editing treatment for a lung and liver disease

2 months ago

#AAD25: What you need to know from Amgen, Bristol Myers, J&J and more

2 months ago

Exclusive: FDA blocks drug and device reviewers from taking HHS' buyout offer

2 months ago

Mired in low expectations, Novo braces for upcoming CagriSema head-to-head trial

2 months ago

J&J, Protagonist outline first IBD win for oral IL-23 with $5B+ sales potential

2 months ago

Trevi’s mid-stage chronic cough data meet ‘home run’ scenario, stock soars

2 months ago

Arrowhead reveals small batch of open-label data for 'non-core' kidney drug

2 months ago

Novo Nordisk’s CagriSema shows 15.7% weight loss in second pivotal trial

2 months ago

Mineralys’ Phase 3 blood pressure pill data support potential FDA approval

2 months ago

Roche launches new research center with Harvard in Boston area

2 months ago

J&J axes Phase 3 depression program due to ‘insufficient efficacy’ shortly after Neumora’s study fail

2 months ago

Novo Nordisk’s rare disease ‘company within a company’ has an open goal in sickle cell

2 months ago

Luxa's stem cell therapy for dry AMD shows early promise

2 months ago

Denali stops some work on ALS drug after analysis showed no impact on key biomarker

2 months ago

Novo Nordisk looks into starting GLP-1 drug trials for addiction

2 months ago

ITM reports more Phase 3 radiopharma data in challenge to Novartis’ Lutathera

2 months ago

FDA puts BioNTech’s malaria vaccine on clinical hold

2 months ago

UK biotech unveils early data for antibiotic in chronic back pain

2 months ago

PepGen delays study for Duchenne drug as it awaits safety data from another trial

2 months ago

Swiss biotech ends Phase 2 study in Alzheimer's shortly after Lilly and Biogen did the same

2 months ago

NIH-backed research tries to use stem cells to restore the eye’s outer layer

2 months ago

GSK, Amgen and AstraZeneca tout Phase 3 data in inflammatory nasal condition

2 months ago

Pliant calls it quits on Phase 2b idiopathic pulmonary fibrosis study

2 months ago

First page Previous page 4 5 678 9 10 Next page Last page